- Home
- SHLS vs PHAR Comparison
SHLS vs PHAR Comparison
Compare SHLS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- PHAR
- Stock Information
- Founded
- SHLS 1996
- PHAR 1988
- Country
- SHLS United States
- PHAR Netherlands
- Employees
- SHLS N/A
- PHAR N/A
- Industry
- SHLS Semiconductors
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- SHLS Technology
- PHAR Health Care
- Exchange
- SHLS Nasdaq
- PHAR Nasdaq
- Market Cap
- SHLS 1.1B
- PHAR 951.7M
- IPO Year
- SHLS 2021
- PHAR N/A
- Fundamental
- Price
- SHLS $10.75
- PHAR $13.75
- Analyst Decision
- SHLS Buy
- PHAR Strong Buy
- Analyst Count
- SHLS 20
- PHAR 3
- Target Price
- SHLS $8.26
- PHAR $30.00
- AVG Volume (30 Days)
- SHLS 7.6M
- PHAR 12.4K
- Earning Date
- SHLS 11-04-2025
- PHAR 11-06-2025
- Dividend Yield
- SHLS N/A
- PHAR N/A
- EPS Growth
- SHLS N/A
- PHAR N/A
- EPS
- SHLS 0.12
- PHAR N/A
- Revenue
- SHLS $400,354,000.00
- PHAR $339,836,000.00
- Revenue This Year
- SHLS $18.14
- PHAR $17.70
- Revenue Next Year
- SHLS $14.78
- PHAR $12.25
- P/E Ratio
- SHLS $86.43
- PHAR N/A
- Revenue Growth
- SHLS N/A
- PHAR 22.44
- 52 Week Low
- SHLS $2.71
- PHAR $7.31
- 52 Week High
- SHLS $11.31
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- SHLS 66.40
- PHAR 46.62
- Support Level
- SHLS $9.57
- PHAR $13.08
- Resistance Level
- SHLS $10.79
- PHAR $14.81
- Average True Range (ATR)
- SHLS 0.78
- PHAR 0.55
- MACD
- SHLS 0.04
- PHAR -0.13
- Stochastic Oscillator
- SHLS 78.93
- PHAR 29.12
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.